Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
This Phase II study will test whether CYR-101, a CNS-active compound with novel pharmacological profile and devoid of dopamine D2 receptor binding properties, is efficacious when administered orally in the management of patients with a diagnosis of DSM-IV schizophrenia.
Critère d'inclusion
- Schizophrenia